Solid Biosciences (SLDB) Stock Forecast & Price Target

Compare

1,573 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SLDB Analyst Ratings

Strong Buy

11 Buy

0 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Solid

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SLDB Stock 12 Month Forecast

Average Price Target

$15.00

▲(184.09% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $15.00 with a high forecast of $20.00 and a low forecast of $9.00. The average price target represents a 184.09% change from the last price of $5.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.21,6.3476923076923075,7.485384615384615,8.623076923076923,9.760769230769231,10.898461538461538,12.036153846153844,13.173846153846153,14.311538461538461,15.44923076923077,16.586923076923075,17.724615384615383,18.86230769230769,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.21,5.9630769230769225,6.716153846153846,7.469230769230769,8.222307692307691,8.975384615384614,9.728461538461538,10.48153846153846,11.234615384615385,11.987692307692306,12.74076923076923,13.493846153846153,14.246923076923075,{"y":15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.21,5.501538461538462,5.793076923076923,6.084615384615384,6.376153846153846,6.667692307692308,6.9592307692307696,7.25076923076923,7.542307692307692,7.833846153846154,8.125384615384615,8.416923076923077,8.708461538461538,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$15.00

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Schwartz

Leerink Partners

$20

Buy

278.79%

Upside

Reiterated

12/15/25

Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Progress Drive Buy RatingWe hosted a virtual investor meeting with SLDB management as part of our Genetic Medicines Insights Series, where the conversation focused on their potentially transformational gene therapies in Duchenne muscular dystrophy/DMD, Friedreich's ataxia/FA, and catecholaminergic polymorphic ventricular tachycardia/ CPVT. We were joined by Bo Cumbo (President & CEO) and Kevin Tan (CFO) to discuss SLDB's progress and their outlook 2026.

Gil Blum

Needham

$16

Buy

203.03%

Upside

Initiated

12/04/25

Solid Biosciences initiated with a Buy at NeedhamSolid Biosciences initiated with a Buy at Needham

Sami Corwin

William Blair

Buy

―

Reiterated

11/17/25

Strategic Advancements and Growth Potential: Solid Biosciences' Buy Rating Validated by Key Partnerships and Regulatory Progress

Anupam Rama

J.P. Morgan

$13→$11

Buy

108.33%

Upside

Reiterated

11/05/25

Solid Biosciences (SLDB) Receives a Buy from J.P. Morgan

Arthur He CFA

H.C. Wainwright

$16→$20

Buy

278.79%

Upside

Reiterated

11/05/25

Solid Biosciences (SLDB) Gets a Buy from H.C. Wainwright

Joon Lee

Truist Financial

Buy

―

Reiterated

11/04/25

Truist Financial Sticks to Its Buy Rating for Solid Biosciences (SLDB)

Geulah Livshits

Chardan Capital

$15

Buy

184.09%

Upside

Reiterated

11/04/25

Solid Biosciences (SLDB) Receives a Buy from Chardan Capital

Laura Chico

Wedbush

$14

Buy

165.15%

Upside

Reiterated

11/04/25

Yigal Nochomovitz

Citi

$16→$14

Buy

165.15%

Upside

Reiterated

11/04/25

Solid Biosciences price target lowered to $14 from $16 at CitiSolid Biosciences price target lowered to $14 from $16 at Citi

Gena Wang

Barclays

$10→$9

Buy

70.45%

Upside

Reiterated

11/03/25

Barclays Sticks to Its Buy Rating for Solid Biosciences (SLDB)

Charles Duncan

Cantor Fitzgerald

$16

Buy

203.03%

Upside

Reiterated

09/22/25

Cantor Fitzgerald Sticks to Their Buy Rating for Solid Biosciences (SLDB)

Silvan Tuerkcan

Citizens JMP

$15

Buy

184.09%

Upside

Reiterated

09/12/25

Citizens JMP Sticks to Their Buy Rating for Solid Biosciences (SLDB)

Biren Amin

Piper Sandler

$17

Buy

221.97%

Upside

Reiterated

08/13/25

Piper Sandler Keeps Their Buy Rating on Solid Biosciences (SLDB)

Maury Raycroft

Jefferies

$16→$15

Buy

184.09%

Upside

Reiterated

05/16/25

Solid Biosciences (SLDB) PT Lowered to $15 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Solid Biosciences (NASDAQ: SLDB) to $15.00 (from $16.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Schwartz

Leerink Partners

$20

Buy

278.79%

Upside

Reiterated

12/15/25

Gil Blum

Needham

$16

Buy

203.03%

Upside

Initiated

12/04/25

Solid Biosciences initiated with a Buy at NeedhamSolid Biosciences initiated with a Buy at Needham

Sami Corwin

William Blair

Buy

―

Reiterated

11/17/25

Strategic Advancements and Growth Potential: Solid Biosciences' Buy Rating Validated by Key Partnerships and Regulatory Progress

Anupam Rama

J.P. Morgan

$13→$11

Buy

108.33%

Upside

Reiterated

11/05/25

Solid Biosciences (SLDB) Receives a Buy from J.P. Morgan

Arthur He CFA

H.C. Wainwright

$16→$20

Buy

278.79%

Upside

Reiterated

11/05/25

Solid Biosciences (SLDB) Gets a Buy from H.C. Wainwright

Joon Lee

Truist Financial

Buy

―

Reiterated

11/04/25

Truist Financial Sticks to Its Buy Rating for Solid Biosciences (SLDB)

Geulah Livshits

Chardan Capital

$15

Buy

184.09%

Upside

Reiterated

11/04/25

Solid Biosciences (SLDB) Receives a Buy from Chardan Capital

Laura Chico

Wedbush

$14

Buy

165.15%

Upside

Reiterated

11/04/25

Yigal Nochomovitz

Citi

$16→$14

Buy

165.15%

Upside

Reiterated

11/04/25

Solid Biosciences price target lowered to $14 from $16 at CitiSolid Biosciences price target lowered to $14 from $16 at Citi

Gena Wang

Barclays

$10→$9

Buy

70.45%

Upside

Reiterated

11/03/25

Barclays Sticks to Its Buy Rating for Solid Biosciences (SLDB)

Charles Duncan

Cantor Fitzgerald

$16

Buy

203.03%

Upside

Reiterated

09/22/25

Cantor Fitzgerald Sticks to Their Buy Rating for Solid Biosciences (SLDB)

Silvan Tuerkcan

Citizens JMP

$15

Buy

184.09%

Upside

Reiterated

09/12/25

Citizens JMP Sticks to Their Buy Rating for Solid Biosciences (SLDB)

Biren Amin

Piper Sandler

$17

Buy

221.97%

Upside

Reiterated

08/13/25

Piper Sandler Keeps Their Buy Rating on Solid Biosciences (SLDB)

Maury Raycroft

Jefferies

$16→$15

Buy

184.09%

Upside

Reiterated

05/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Solid Biosciences

1 Month

xxx

Success Rate

6/14 ratings generated profit

Average Return

+2.98%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +2.98% per trade.

3 Months

xxx

Success Rate

7/14 ratings generated profit

Average Return

+10.31%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +10.31% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

7/13 ratings generated profit

Average Return

+0.58%

reiterated a buy rating 5 days ago

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +0.58% per trade.

2 Years

xxx

Success Rate

7/14 ratings generated profit

Average Return

+4.89%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +4.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLDB Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SLDB has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SLDB average Analyst price target in the past 3 months is 15.00.

Each month's total comprises the sum of three months' worth of ratings.

SLDB Financial Forecast

SLDB Earnings Forecast

Next quarter’s earnings estimate for SLDB is -$0.51 with a range of -$0.63 to -$0.38. The previous quarter’s EPS was -$0.48. SLDB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SLDB has Performed in-line its overall industry.

SLDB Sales Forecast

Next quarter’s sales forecast for SLDB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SLDB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SLDB has Performed in-line its overall industry.

SLDB Stock Forecast FAQ

What is SLDB’s average 12-month price target, according to analysts?

Based on analyst ratings, Solid Biosciences’s 12-month average price target is 15.00.

What is SLDB’s upside potential, based on the analysts’ average price target?

Solid Biosciences has 184.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SLDB a Buy, Sell or Hold?

Solid Biosciences has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is Solid Biosciences’s price target?

The average price target for Solid Biosciences is 15.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $9.00. The average price target represents 184.09% Increase from the current price of $5.28.

What do analysts say about Solid Biosciences?

Solid Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of SLDB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Solid Biosciences (SLDB) Stock Forecast & Price Target

SLDB Analyst Ratings

SLDB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Solid Biosciences

SLDB Analyst Recommendation Trends

SLDB Financial Forecast

SLDB Earnings Forecast

SLDB Sales Forecast

SLDB Stock Forecast FAQ

Detailed List of Analyst Forecasts